Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies

PURPOSE: Fruquintinib is an anti-vascular endothelial growth factor receptor (VEGFR) agent. The FRESCO trial demonstrated that patients with metastatic colorectal cancer (mCRC) refractory to standard therapies could benefit from fruquintinib with tolerable adverse events (AEs). However, the efficacy...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Front Oncol
मुख्य लेखकों: Wang, Lei, Cao, Huijiao, Jiang, Chang, He, Wenzhuo, You, Yafei, Peng, Kunwei, Jin, Yanan, Xia, Liangping
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Frontiers Media S.A. 2020
विषय:
Oncology
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7691567/
https://ncbi.nlm.nih.gov/pubmed/33282739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.587692
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन